

Declaration form on Nothing to Declare or Nothing New to Declare for use in the information exchange

Measure	Nothing to declare	Nothing new to declare	Year of last declaration if nothing new to declare
A, part 1	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
A, part 2 (i)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
A, part 2 (ii)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
A, part 2 (iii)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
B	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
E	<input type="checkbox"/>	<input checked="" type="checkbox"/>	2015
F	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
G	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Date: 5 April 2023

State Party to the Convention: Republic of Estonia

Date of ratification/accession to the Convention: 21 June 1993

National point of contact: Department, Ministry of Foreign affairs of the Republic of Estonia

Islandi väljak 1

15049 Tallinn

Phone: (+372)

E-mail: natoat3buroo@mfa.ee

Confidence-Building Measure "A"

Part 1 Exchange of data on research centres and laboratories

States Parties that do not possess a facility meeting criteria for such maximum containment should continue to Form A, part 1 (ii).

Form A, part 1 (i)

Estonia do not possess a facility meeting criteria for BSL 4.

Form A, part 1 (ii)

If no BSL4 facility is declared in Form A, part 1 (i), indicate the highest biosafety level implemented in facilities handling biological agents¹ on a State Party's territory:

Biosafety level 3 ²	yes
--------------------------------	-----

BSL 3 laboratories in Estonia: Joint Laboratories of Tartu University Clinics, University of Tartu Institute of Technology, Laboratory of Communicable Diseases of Estonian Health Board, Synlab Eesti, Microbiology Laboratory of North-Estonia Regional Hospital, The National Centre for Laboratory Research and Risk Assessment (LABRIS), Laboratory for Mycobacteriosis of University of Life Sciences; Icosagen Cell Factory OÜ.

Part 2

Exchange of information on national biological defence research and development programmes

Estonia is not running national biological defence research and development programmes.

Form A, part 2 (i)

National biological defence research and development programmes Declaration

Are there any national programmes to conduct biological defence research and development within the territory of the State Party, under its jurisdiction or control anywhere? Activities of such programmes would include prophylaxis, studies on pathogenicity and virulence, diagnostic techniques,

¹ Microorganisms pathogenic to humans and/or animals

² In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

aerobiology, detection, treatment, toxicology, physical protection, decontamination and other related research.

No

If the answer is Yes, complete Form A, part 2 (ii) which will provide a description of each programme.

Form A, part 2 (ii)

National biological defence research and development programmes

Description

Non

Form A, part 2 (iii)

National biological defence research and development programmes

Facilities

Non

Confidence-Building Measure "B"

Exchange of information on outbreaks of infectious diseases and similar occurrences caused by toxins

Form B

Information on outbreaks of infectious diseases and similar occurrences, that seem to deviate from the normal pattern³

There were no cases (except cases and clusters/outbreaks of COVID-19) for the 2022 reporting period on outbreaks of infectious diseases and similar occurrences caused by toxins that seem to deviate from the normal pattern.

During the period 1.01-31.12.2022 were newly registered 370 262 cases of COVID-19 in Estonia.

We report the information with respect to infectious diseases of humans covering the years 2015-2022 in Estonia.

Diseases	Number of cases							
	2015	2016	2017	2018	2019	2020	2021	2022
Acquired immunodeficiency syndrome (AIDS)	19	41	20	25	28	26	12	13
Human immunodeficiency virus infection (HIV)	270	229	219	190	178	147	125	250
Anthrax	0	0	0	0	0	0	0	0

³ See paragraph 2 of the chapeau to Confidence-Building Measure B.

Diseases	Number of cases							
	2015	2016	2017	2018	2019	2020	2021	2022
Avian influenza A/H5 or A/H5N1 in humans	0	0	0	0	0	0	0	0
Botulism	0	0	0	3	0	0	0	0
Brucellosis	0	0	0	1	1	0	0	0
Campylobacteriosis	364	382	347	411	348	265	185	211
Chlamydia infection, gen.	1351	1275	1139	983	1090	935	994	1039
Cholera	0	0	0	0	0	0	0	0
COVID-19	-	-	-	-	-	28406	213710	370262
Creutzfeldt-Jakob disease (sporadic)	0	0	0	1	1	0	4	1
Cryptosporidiosis	4	1	0	3	0	5	7	12
Diphtheria	0	0	0	0	0	0	0	0
Echinococcosis	0	0	1	0	2	1	4	1
Escherichia coli infection (STEC/VTEC)	8	5	3	7	6	10	7	11
Giardiasis	181	187	161	107	121	86	44	15
Gonorrhoea	121	96	58	49	81	23	52	117
<i>Haemophilus influenzae</i> infection	49	48	53	75	69	36	18	44
Hepatitis A	6	7	45	15	20	30	7	20
Hepatitis B, acute	6	8	4	4	3	2	3	2
Hepatitis C, acute	10	15	6	5	8	12	5	6
Influenza	3703	8584	7408	14300	11668	4198	372	21489
incl. influenza A(H1N1)	5	169	1	35	197	40	0	36
Legionnaires' disease	6	14	16	18	12	18	10	14
Leptospirosis	2	3	5	6	5	10	8	9
Listeriosis	11	9	4	28	22	3	5	11
Malaria (imported)	4	1	2	3	3	1	3	4
Measles	4	2	1	10	27	0	0	0
Meningococcal disease, invasive	4	5	4	7	3	4	3	1
Mumps	3	4	6	6	4	3	0	4
Pertussis	77	74	56	69	135	44	13	8
Pneumococcal infection	90	143	160	195	220	82	78	110
Poliomyelitis	0	0	0	0	0	0	0	0
Q fever	0	0	0	0	0	0	0	0
Rabies	0	0	0	0	0	0	0	0
Rubella	0	0	0	0	0	0	0	0
Rubella, congenital	0	0	0	0	0	0	0	0
Salmonellosis	118	358	279	323	154	92	114	134
Shigellosis	12	17	16	17	29	4	2	10
Syphilis	25	27	37	24	40	30	34	39
Syphilis, congenital and neonatal	0	0	0	0	0	0	0	0
Tetanus	0	0	1	1	0	0	0	0
Toxoplasmosis, congenital	0	0	0	1	0	0	0	0
Trichinellosis	2	0	0	0	0	0	0	1
Tuberculosis, primary	166	163	144	120	125	109	92	104

Diseases	Number of cases							
	2015	2016	2017	2018	2019	2020	2021	2022
Tularaemia	0	1	0	1	2	1	1	3
Typhoid/Paratyphoid fever	2/0	0/0	2/0	0/2	2/0	0/0	1/0	1/2
Viral haemorrhagic fever with renal syndrome	14	11	25	15	26	17	11	13
West Nile fever	0	0	0	0	0	0	0	0
Yellow fever	0	0	0	0	0	0	0	0
Yersiniosis	53	45	43	63	42	44	45	53
Lyme disease	1402	1420	1963	2284	2313	2752	2471	3075
Tick-borne encephalitis	116	81	87	85	83	70	82	140

Confidence-Building Measure "C

Encouragement of publication of results and promotion of use of knowledge

No overview on publication of results and promotion of use of knowledge.

Confidence-Building Measure "E

Form E

Declaration of legislation, regulations and other measures

Relating to	Legislation	Regulations	Other measures ⁴	Amended since last year
(a) Development, production stockpiling, acquisition or retention of microbial or other biological agents, or toxins, weapons, equipment and means of delivery specified in Article I	No	No	Yes	No
(b) Exports of micro-organisms ⁵ and toxins	No	No	Yes	No
(c) Imports of micro-organisms ¹¹ and toxins	No	No	Yes	No
(d) Biosafety ⁶ and biosecurity ⁷	Yes	Yes	No	No

⁴ Including guidelines.

⁵ Micro-organisms pathogenic to man, animals and plants in accordance with the Convention.

⁶ In accordance with the latest version of the WHO Laboratory Biosafety Manual or equivalent national or international guidance.

⁷ In accordance with the latest version of the WHO Laboratory Biosecurity Guidance or equivalent national or international guidance.

Exports of micro-organisms and toxins are regulated by the EC Council Regulation and UN Recommendations with amendments of the United Nations Committee of Experts on the Transport of Dangerous Goods. Imports of micro-organisms and toxins are regulated by the EC Council Directives.

Transport of dangerous biological substances is regulated by the WHO Guidance on regulations for the Transport of Infectious Substances, 2021-2022.

Estonian Health Board Guidance for the Transport of Infectious Substances. EC Council Directive 2008/68/EC and updated Annexes on the inland transport of dangerous goods.

Estonian Communicable Diseases Act 2003 (updated version in force 1.04.2023).

Biosafety is regulated by the Occupational Health and Safety Act 1999 (updated version in force 1.07.2023).

Regulations No. 144 of 5 May 2000 on occupational safety and health requirements for the working environment affected by biological risk factors (updated version in force 14.08.2021)

Biosafety regulations overlap with biosecurity; no specific biosecurity legislation exists.

Under the Estonian Communicable Diseases Act 2003 Health Board is responsible for issuing activity licenses for all laboratories handling infectious material.

Activity licenses is valid for five years as of the issue thereof.

Official control is organized under the process of licensing. A decision to issue an activity license shall be published in the official publication Ametlikud Teadaanded <https://www.rik.ee/en/official-announcements>.

Confidence-Building Measure "F"

Form F

Declaration of past activities in offensive and/or defensive biological research and development programmes

There have not been any activities in offensive and/or defensive biological research and development programmes.

Confidence-Building Measure "G"

Form G

Declaration of vaccine production facilities

There are no vaccine production facilities in Estonia.